{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T23:39:33Z","timestamp":1795045173257,"version":"4.10.2"},"reference-count":148,"publisher":"American Society of Hematology","issue":"12","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,3,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chronic myeloid leukemia (CML) is caused by the acquisition of the tyrosine kinase BCR-ABL1 in a hemopoietic stem cell, transforming it into a leukemic stem cell (LSC) that self-renews, proliferates, and differentiates to give rise to a myeloproliferative disease. Although tyrosine kinase inhibitors (TKIs) that target the kinase activity of BCR-ABL1 have transformed CML from a once-fatal disease to a manageable one for the vast majority of patients, only \u223c10% of those who present in chronic phase (CP) can discontinue TKI treatment and maintain a therapy-free remission. Strong evidence now shows that CML LSCs are resistant to the effects of TKIs and persist in all patients on long-term therapy, where they may promote acquired TKI resistance, drive relapse or disease progression, and inevitably represent a bottleneck to cure. Since their discovery in patients almost 2 decades ago, CML LSCs have become a well-recognized exemplar of the cancer stem cell and have been characterized extensively, with the aim of developing new curative therapeutic approaches based on LSC eradication. This review summarizes our current understanding of many of the pathways and mechanisms that promote the survival of the CP CML LSCs and how they can be a source of new gene coding mutations that impact in the clinic. We also review recent preclinical approaches that show promise to eradicate the LSC, and future challenges on the path to cure.<\/jats:p>","DOI":"10.1182\/blood-2016-09-696013","type":"journal-article","created":{"date-parts":[[2017,2,3]],"date-time":"2017-02-03T21:00:16Z","timestamp":1486155616000},"page":"1595-1606","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":275,"title":["The chronic myeloid leukemia stem cell: stemming the tide of persistence"],"prefix":"10.1182","volume":"129","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0608-6066","authenticated-orcid":false,"given":"Tessa L.","family":"Holyoake","sequence":"first","affiliation":[{"name":"Paul O\u2019Gorman Leukaemia Research Centre and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2075-4662","authenticated-orcid":false,"given":"David","family":"Vetrie","sequence":"additional","affiliation":[{"name":"Epigenetics Unit, Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111903584717000_B1","first-page":"1013","article-title":"Chromosome studies in human leukemia. II. Chronic granulocytic leukemia","volume":"27","author":"Nowell","year":"1961","journal-title":"J Natl Cancer Inst"},{"issue":"5405","key":"2019111903584717000_B2","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"issue":"5940","key":"2019111903584717000_B3","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/306239a0","article-title":"Localization of the c-ab1 oncogene adjacent to a translocation break point in chronic myelocytic leukaemia","volume":"306","author":"Heisterkamp","year":"1983","journal-title":"Nature"},{"issue":"3597","key":"2019111903584717000_B4","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1126\/science.142.3597.1305","article-title":"Persistent mitosis of transfused homologous leukocytes in children receiving antileukemic therapy","volume":"142","author":"Levin","year":"1963","journal-title":"Science"},{"issue":"6","key":"2019111903584717000_B5","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1182\/blood.V88.6.2162.bloodjournal8862162","article-title":"Characterization of primitive subpopulations of normal and leukemic cells present in the blood of patients with newly diagnosed as well as established chronic myeloid leukemia","volume":"88","author":"Petzer","year":"1996","journal-title":"Blood"},{"issue":"6","key":"2019111903584717000_B6","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.ccr.2004.10.015","article-title":"MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors","volume":"6","author":"Huntly","year":"2004","journal-title":"Cancer Cell"},{"issue":"4944","key":"2019111903584717000_B7","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1126\/science.2406902","article-title":"Induction of chronic myelogenous leukemia in mice by the P210bcr\/abl gene of the Philadelphia chromosome","volume":"247","author":"Daley","year":"1990","journal-title":"Science"},{"issue":"9","key":"2019111903584717000_B8","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1182\/blood-2003-03-0768","article-title":"Inducible expression of BCR\/ABL using human CD34 regulatory elements results in a megakaryocytic myeloproliferative syndrome","volume":"102","author":"Huettner","year":"2003","journal-title":"Blood"},{"issue":"1","key":"2019111903584717000_B9","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1182\/blood-2003-12-4369","article-title":"Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis","volume":"105","author":"Koschmieder","year":"2005","journal-title":"Blood"},{"issue":"1","key":"2019111903584717000_B10","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.celrep.2013.08.037","article-title":"Expression of BCR\/ABL p210 from a knockin allele enhances bone marrow engraftment without inducing neoplasia","volume":"5","author":"Foley","year":"2013","journal-title":"Cell Reports"},{"issue":"9216","key":"2019111903584717000_B11","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/S0140-6736(00)02241-8","article-title":"Evidence from a leukaemia model for maintenance of vascular endothelium by bone-marrow-derived endothelial cells","volume":"355","author":"Gunsilius","year":"2000","journal-title":"Lancet"},{"issue":"7","key":"2019111903584717000_B12","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1182\/blood-2004-07-2514","article-title":"Identification of human chronic myelogenous leukemia progenitor cells with hemangioblastic characteristics","volume":"105","author":"Fang","year":"2005","journal-title":"Blood"},{"issue":"4","key":"2019111903584717000_B13","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/jb\/mvr016","article-title":"TGF-beta1-induced PI3K\/Akt\/NF-kappaB\/MMP9 signalling pathway is activated in Philadelphia chromosome-positive chronic myeloid leukaemia hemangioblasts","volume":"149","author":"Zhu","year":"2011","journal-title":"J Biochem"},{"issue":"5","key":"2019111903584717000_B14","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/cgt.2014.65","article-title":"BCR\/ABL oncogene-induced PI3K signaling pathway leads to chronic myeloid leukemia pathogenesis by impairing immuno-modulatory function of hemangioblasts","volume":"22","author":"Li","year":"2015","journal-title":"Cancer Gene Ther"},{"issue":"3","key":"2019111903584717000_B15","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.beha.2009.07.007","article-title":"Epidemiology of chronic myeloid leukaemia (CML)","volume":"22","author":"Rohrbacher","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"issue":"Suppl 2","key":"2019111903584717000_B16","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1269\/jrr.32.SUPPLEMENT2_14","article-title":"Atomic bomb and leukemia","volume":"32","author":"Ichimaru","year":"1991","journal-title":"J Radiat Res (Tokyo)"},{"issue":"2","key":"2019111903584717000_B17","first-page":"152","article-title":"The natural history of chronic myelogenous leukemia in the interferon era","volume":"32","author":"Giralt","year":"1995","journal-title":"Semin Hematol"},{"issue":"11","key":"2019111903584717000_B18","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.1182\/blood-2003-12-4111","article-title":"The biology of CML blast crisis","volume":"103","author":"Calabretta","year":"2004","journal-title":"Blood"},{"issue":"1","key":"2019111903584717000_B19","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1182\/blood-2005-05-2155","article-title":"Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML","volume":"107","author":"Yong","year":"2006","journal-title":"Blood"},{"issue":"7","key":"2019111903584717000_B20","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/j.cell.2015.11.013","article-title":"Transcriptional heterogeneity and lineage commitment in myeloid progenitors [published correction appears in Cell. 2016;164(1-2):325]","volume":"163","author":"Paul","year":"2015","journal-title":"Cell"},{"issue":"18","key":"2019111903584717000_B21","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1182\/blood-2013-06-508432","article-title":"Analysis of the clonal growth and differentiation dynamics of primitive barcoded human cord blood cells in NSG mice","volume":"122","author":"Cheung","year":"2013","journal-title":"Blood"},{"key":"2019111903584717000_B22","doi-asserted-by":"crossref","first-page":"11075","DOI":"10.1038\/ncomms11075","article-title":"Single-cell RNA sequencing reveals molecular and functional platelet bias of aged haematopoietic stem cells","volume":"7","author":"Grover","year":"2016","journal-title":"Nat Commun"},{"issue":"6269","key":"2019111903584717000_B23","doi-asserted-by":"crossref","first-page":"aab2116","DOI":"10.1126\/science.aab2116","article-title":"Distinct routes of lineage development reshape the human blood hierarchy across ontogeny","volume":"351","author":"Notta","year":"2016","journal-title":"Science"},{"issue":"7488","key":"2019111903584717000_B24","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nature13038","article-title":"Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia [published correction appears in Nature. 2014 Apr 17;508(7496):420]","volume":"506","author":"Shlush","year":"2014","journal-title":"Nature"},{"issue":"12","key":"2019111903584717000_B25","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1038\/leu.2014.272","article-title":"Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status","volume":"28","author":"Schmidt","year":"2014","journal-title":"Leukemia"},{"issue":"8","key":"2019111903584717000_B26","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.1182\/blood.V86.8.3118.3118","article-title":"Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals","volume":"86","author":"Biernaux","year":"1995","journal-title":"Blood"},{"issue":"9","key":"2019111903584717000_B27","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1182\/blood.V92.9.3362.421k17_3362_3367","article-title":"The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease","volume":"92","author":"Bose","year":"1998","journal-title":"Blood"},{"issue":"26","key":"2019111903584717000_B28","doi-asserted-by":"crossref","first-page":"9194","DOI":"10.1073\/pnas.0503280102","article-title":"Cell intrinsic alterations underlie hematopoietic stem cell aging","volume":"102","author":"Rossi","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"2019111903584717000_B29","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.stem.2013.01.017","article-title":"Proliferation-dependent alterations of the DNA methylation landscape underlie hematopoietic stem cell aging","volume":"12","author":"Beerman","year":"2013","journal-title":"Cell Stem Cell"},{"issue":"5","key":"2019111903584717000_B30","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat Med"},{"issue":"11","key":"2019111903584717000_B31","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N Engl J Med"},{"issue":"8","key":"2019111903584717000_B32","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrc3317","article-title":"Pushing the limits of targeted therapy in chronic myeloid leukaemia","volume":"12","author":"O\u2019Hare","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"2019111903584717000_B33","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"issue":"4","key":"2019111903584717000_B34","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","article-title":"Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study","volume":"122","author":"Ross","year":"2013","journal-title":"Blood"},{"issue":"18","key":"2019111903584717000_B35","doi-asserted-by":"crossref","first-page":"4264","DOI":"10.1182\/blood-2011-11-393041","article-title":"BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and management","volume":"119","author":"Branford","year":"2012","journal-title":"Blood"},{"issue":"6","key":"2019111903584717000_B36","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"issue":"5","key":"2019111903584717000_B37","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood-2010-12-326405","article-title":"BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet","volume":"118","author":"Soverini","year":"2011","journal-title":"Blood"},{"issue":"13","key":"2019111903584717000_B38","doi-asserted-by":"crossref","first-page":"6192","DOI":"10.1073\/pnas.89.13.6192","article-title":"Rapid decline of chronic myeloid leukemic cells in long-term culture due to a defect at the leukemic stem cell level","volume":"89","author":"Udomsakdi","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"2019111903584717000_B39","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1182\/blood.V94.6.2056","article-title":"Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia","volume":"94","author":"Holyoake","year":"1999","journal-title":"Blood"},{"issue":"12","key":"2019111903584717000_B40","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1182\/blood-2002-09-2780","article-title":"Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment","volume":"101","author":"Bhatia","year":"2003","journal-title":"Blood"},{"issue":"20","key":"2019111903584717000_B41","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.1182\/blood-2010-12-327437","article-title":"Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment","volume":"118","author":"Chu","year":"2011","journal-title":"Blood"},{"issue":"13","key":"2019111903584717000_B42","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1182\/blood-2011-02-335497","article-title":"Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease","volume":"118","author":"Chomel","year":"2011","journal-title":"Blood"},{"issue":"23","key":"2019111903584717000_B43","doi-asserted-by":"crossref","first-page":"35293","DOI":"10.18632\/oncotarget.9182","article-title":"Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation","volume":"7","author":"Chomel","year":"2016","journal-title":"Oncotarget"},{"issue":"2","key":"2019111903584717000_B44","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1182\/blood-2010-08-303495","article-title":"Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinib","volume":"119","author":"Kumari","year":"2012","journal-title":"Blood"},{"issue":"1","key":"2019111903584717000_B45","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/ajh.21915","article-title":"Characterization of chronic myeloid leukemia stem cells","volume":"86","author":"Gerber","year":"2011","journal-title":"Am J Hematol"},{"issue":"1","key":"2019111903584717000_B46","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro","volume":"99","author":"Graham","year":"2002","journal-title":"Blood"},{"issue":"11","key":"2019111903584717000_B47","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","article-title":"Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction","volume":"107","author":"Copland","year":"2006","journal-title":"Blood"},{"issue":"20","key":"2019111903584717000_B48","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.1182\/blood-2012-11-466938","article-title":"Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells","volume":"121","author":"Bolton-Gillespie","year":"2013","journal-title":"Blood"},{"issue":"18","key":"2019111903584717000_B49","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.1182\/blood-2011-10-385658","article-title":"Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors","volume":"119","author":"Nieborowska-Skorska","year":"2012","journal-title":"Blood"},{"issue":"8","key":"2019111903584717000_B50","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1158\/0008-5472.CAN-07-6858","article-title":"BCR\/ABL inhibits mismatch repair to protect from apoptosis and induce point mutations","volume":"68","author":"Stoklosa","year":"2008","journal-title":"Cancer Res"},{"issue":"4","key":"2019111903584717000_B51","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1080\/03093640701859089","article-title":"BCR\/ABL, DNA damage and DNA repair: implications for new treatment concepts","volume":"49","author":"Skorski","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"17","key":"2019111903584717000_B52","doi-asserted-by":"crossref","first-page":"6884","DOI":"10.1158\/0008-5472.CAN-08-1101","article-title":"BCR\/ABL and other kinases from chronic myeloproliferative disorders stimulate single-strand annealing, an unfaithful DNA double-strand break repair","volume":"68","author":"Cramer","year":"2008","journal-title":"Cancer Res"},{"issue":"9","key":"2019111903584717000_B53","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.1182\/blood-2006-11-057521","article-title":"Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells","volume":"109","author":"J\u00f8rgensen","year":"2007","journal-title":"Blood"},{"issue":"6","key":"2019111903584717000_B54","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1182\/blood-2010-12-326843","article-title":"Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival","volume":"119","author":"Hamilton","year":"2012","journal-title":"Blood"},{"issue":"1","key":"2019111903584717000_B55","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1172\/JCI35721","article-title":"Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity","volume":"121","author":"Corbin","year":"2011","journal-title":"J Clin Invest"},{"issue":"11","key":"2019111903584717000_B56","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1084\/jem.20110304","article-title":"BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia","volume":"208","author":"Hurtz","year":"2011","journal-title":"J Exp Med"},{"issue":"9","key":"2019111903584717000_B57","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1002\/stem.1748","article-title":"The antiproliferative activity of kinase inhibitors in chronic myeloid leukemia cells is mediated by FOXO transcription factors","volume":"32","author":"Pellicano","year":"2014","journal-title":"Stem Cells"},{"issue":"7281","key":"2019111903584717000_B58","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nature08734","article-title":"TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia","volume":"463","author":"Naka","year":"2010","journal-title":"Nature"},{"issue":"11","key":"2019111903584717000_B59","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1084\/jem.20112087","article-title":"Assembling defenses against therapy-resistant leukemic stem cells: Bcl6 joins the ranks","volume":"208","author":"Pellicano","year":"2011","journal-title":"J Exp Med"},{"issue":"7239","key":"2019111903584717000_B60","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/nature07737","article-title":"Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia","volume":"458","author":"Zhao","year":"2009","journal-title":"Nature"},{"issue":"3","key":"2019111903584717000_B61","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ccr.2008.08.003","article-title":"Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation","volume":"14","author":"Dierks","year":"2008","journal-title":"Cancer Cell"},{"key":"2019111903584717000_B62","doi-asserted-by":"crossref","first-page":"25476","DOI":"10.1038\/srep25476","article-title":"Deregulated hedgehog pathway signaling is inhibited by the smoothened antagonist LDE225 (Sonidegib) in chronic phase chronic myeloid leukaemia","volume":"6","author":"Irvine","year":"2016","journal-title":"Sci Rep"},{"issue":"6938","key":"2019111903584717000_B63","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/nature01593","article-title":"A role for Wnt signalling in self-renewal of haematopoietic stem cells","volume":"423","author":"Reya","year":"2003","journal-title":"Nature"},{"issue":"6","key":"2019111903584717000_B64","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.ccr.2007.11.003","article-title":"Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo","volume":"12","author":"Zhao","year":"2007","journal-title":"Cancer Cell"},{"issue":"4","key":"2019111903584717000_B65","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.stem.2012.02.017","article-title":"Genetic and pharmacologic inhibition of \u03b2-catenin targets imatinib-resistant leukemia stem cells in CML","volume":"10","author":"Heidel","year":"2012","journal-title":"Cell Stem Cell"},{"issue":"2","key":"2019111903584717000_B66","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1172\/JCI45977","article-title":"CD27 signaling on chronic myelogenous leukemia stem cells activates Wnt target genes and promotes disease progression","volume":"122","author":"Sch\u00fcrch","year":"2012","journal-title":"J Clin Invest"},{"issue":"298","key":"2019111903584717000_B67","doi-asserted-by":"crossref","first-page":"298ra119","DOI":"10.1126\/scitranslmed.aab1740","article-title":"Tyrosine kinase inhibitor-induced CD70 expression mediates drug resistance in leukemia stem cells by activating Wnt signaling","volume":"7","author":"Riether","year":"2015","journal-title":"Sci Transl Med"},{"issue":"1","key":"2019111903584717000_B68","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ccr.2010.04.025","article-title":"Wnt\/Ca2+\/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl","volume":"18","author":"Gregory","year":"2010","journal-title":"Cancer Cell"},{"issue":"7","key":"2019111903584717000_B69","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/ng.389","article-title":"Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia","volume":"41","author":"Chen","year":"2009","journal-title":"Nat Genet"},{"issue":"49","key":"2019111903584717000_B70","doi-asserted-by":"crossref","first-page":"31704","DOI":"10.1074\/jbc.271.49.31704","article-title":"P210 and P190(BCR\/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members","volume":"271","author":"Ilaria","year":"1996","journal-title":"J Biol Chem"},{"issue":"12","key":"2019111903584717000_B71","doi-asserted-by":"crossref","first-page":"4917","DOI":"10.1182\/blood-2005-10-4110","article-title":"STAT5 signaling is required for the efficient induction and maintenance of CML in mice","volume":"107","author":"Ye","year":"2006","journal-title":"Blood"},{"issue":"8","key":"2019111903584717000_B72","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1182\/blood-2005-08-3087","article-title":"Enhanced sensitivity to inhibition of SHP2, STAT5, and Gab2 expression in chronic myeloid leukemia (CML)","volume":"107","author":"Scherr","year":"2006","journal-title":"Blood"},{"issue":"3","key":"2019111903584717000_B73","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/leu.2010.287","article-title":"Janus kinase 2 regulates Bcr-Abl signaling in chronic myeloid leukemia","volume":"25","author":"Samanta","year":"2011","journal-title":"Leukemia"},{"issue":"9","key":"2019111903584717000_B74","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1182\/blood-2013-12-545640","article-title":"JAK2\/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo","volume":"124","author":"Gallipoli","year":"2014","journal-title":"Blood"},{"issue":"3","key":"2019111903584717000_B75","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/nchembio.775","article-title":"BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia","volume":"8","author":"Hantschel","year":"2012","journal-title":"Nat Chem Biol"},{"issue":"5","key":"2019111903584717000_B76","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ccr.2005.10.015","article-title":"The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR\/ABL-regulated SET protein","volume":"8","author":"Neviani","year":"2005","journal-title":"Cancer Cell"},{"issue":"10","key":"2019111903584717000_B77","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1172\/JCI68951","article-title":"PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells","volume":"123","author":"Neviani","year":"2013","journal-title":"J Clin Invest"},{"issue":"6","key":"2019111903584717000_B78","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/jnci\/djt006","article-title":"Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex","volume":"105","author":"Chen","year":"2013","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"2019111903584717000_B79","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1038\/leu.2011.325","article-title":"Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors","volume":"26","author":"Traer","year":"2012","journal-title":"Leukemia"},{"issue":"3","key":"2019111903584717000_B80","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/leu.2014.245","article-title":"Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia","volume":"29","author":"Eiring","year":"2015","journal-title":"Leukemia"},{"issue":"12","key":"2019111903584717000_B81","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1182\/blood-2004-05-1941","article-title":"BCR\/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks","volume":"104","author":"Nowicki","year":"2004","journal-title":"Blood"},{"issue":"7","key":"2019111903584717000_B82","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1182\/blood-2013-05-501072","article-title":"Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile","volume":"122","author":"Cramer-Morales","year":"2013","journal-title":"Blood"},{"issue":"10","key":"2019111903584717000_B83","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1038\/nm1489","article-title":"Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells","volume":"12","author":"Krause","year":"2006","journal-title":"Nat Med"},{"issue":"9","key":"2019111903584717000_B84","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood-2013-11-538694","article-title":"Selectins and their ligands are required for homing and engraftment of BCR-ABL1+ leukemic stem cells in the bone marrow niche","volume":"123","author":"Krause","year":"2014","journal-title":"Blood"},{"issue":"42","key":"2019111903584717000_B85","doi-asserted-by":"crossref","first-page":"17468","DOI":"10.1073\/pnas.1111138108","article-title":"Galectin-3 (Gal-3) induced by leukemia microenvironment promotes drug resistance and bone marrow lodgment in chronic myelogenous leukemia","volume":"108","author":"Yamamoto-Sugitani","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"2019111903584717000_B86","doi-asserted-by":"crossref","first-page":"3883","DOI":"10.1182\/blood.V87.9.3883.bloodjournal8793883","article-title":"Interferon-alpha restores normal beta 1 integrin-mediated inhibition of hematopoietic progenitor proliferation by the marrow microenvironment in chronic myelogenous leukemia","volume":"87","author":"Bhatia","year":"1996","journal-title":"Blood"},{"issue":"1","key":"2019111903584717000_B87","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1172\/JCI117333","article-title":"Interferon-alpha restores normal adhesion of chronic myelogenous leukemia hematopoietic progenitors to bone marrow stroma by correcting impaired beta 1 integrin receptor function","volume":"94","author":"Bhatia","year":"1994","journal-title":"J Clin Invest"},{"issue":"10","key":"2019111903584717000_B88","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1182\/blood-2012-02-412890","article-title":"Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-\u03b2-catenin signaling","volume":"121","author":"Zhang","year":"2013","journal-title":"Blood"},{"issue":"5","key":"2019111903584717000_B89","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/leu.2011.291","article-title":"Role of stromal microenvironment in nonpharmacological resistance of CML to imatinib through Lyn\/CXCR4 interactions in lipid rafts","volume":"26","author":"Tabe","year":"2012","journal-title":"Leukemia"},{"issue":"25","key":"2019111903584717000_B90","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1182\/blood-2013-10-536078","article-title":"Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia","volume":"123","author":"Herrmann","year":"2014","journal-title":"Blood"},{"issue":"4","key":"2019111903584717000_B91","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.ccr.2012.02.018","article-title":"Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia","volume":"21","author":"Zhang","year":"2012","journal-title":"Cancer Cell"},{"issue":"5","key":"2019111903584717000_B92","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.ccell.2015.04.004","article-title":"Treatment of chronic myelogenous leukemia by blocking cytokine alterations found in normal stem and progenitor cells","volume":"27","author":"Welner","year":"2015","journal-title":"Cancer Cell"},{"issue":"5","key":"2019111903584717000_B93","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.ccr.2011.10.012","article-title":"IL-6 controls leukemic multipotent progenitor cell fate and contributes to chronic myelogenous leukemia development","volume":"20","author":"Reynaud","year":"2011","journal-title":"Cancer Cell"},{"issue":"1","key":"2019111903584717000_B94","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11899-013-0190-1","article-title":"Immunology and immunotherapy of chronic myeloid leukemia","volume":"9","author":"Ilander","year":"2014","journal-title":"Curr Hematol Malig Rep"},{"issue":"8","key":"2019111903584717000_B95","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1182\/blood-2008-09-179697","article-title":"Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression","volume":"114","author":"Mumprecht","year":"2009","journal-title":"Blood"},{"issue":"8","key":"2019111903584717000_B96","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1038\/leu.2015.26","article-title":"Blocking programmed cell death 1 in combination with adoptive cytotoxic T-cell transfer eradicates chronic myelogenous leukemia stem cells","volume":"29","author":"Riether","year":"2015","journal-title":"Leukemia"},{"issue":"2","key":"2019111903584717000_B97","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1182\/blood-2016-09-742049","article-title":"CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression","volume":"129","author":"Tarafdar","year":"2017","journal-title":"Blood"},{"issue":"7607","key":"2019111903584717000_B98","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nature18288","article-title":"Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells","volume":"534","author":"Abraham","year":"2016","journal-title":"Nature"},{"issue":"8","key":"2019111903584717000_B99","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.18632\/oncotarget.3551","article-title":"Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery","volume":"6","author":"Fu","year":"2015","journal-title":"Oncotarget"},{"issue":"11","key":"2019111903584717000_B100","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1158\/2159-8290.CD-15-1439","article-title":"Chronic myelogenous leukemia-initiating cells require Polycomb group protein EZH2","volume":"6","author":"Xie","year":"2016","journal-title":"Cancer Discov"},{"issue":"11","key":"2019111903584717000_B101","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1158\/2159-8290.CD-16-0263","article-title":"Epigenetic reprogramming sensitizes CML stem cells to combined EZH2 and tyrosine kinase inhibition","volume":"6","author":"Scott","year":"2016","journal-title":"Cancer Discov"},{"issue":"7569","key":"2019111903584717000_B102","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/nature15248","article-title":"Erosion of the chronic myeloid leukaemia stem cell pool by PPAR\u03b3 agonists","volume":"525","author":"Prost","year":"2015","journal-title":"Nature"},{"key":"2019111903584717000_B103","doi-asserted-by":"crossref","first-page":"e377","DOI":"10.1038\/bcj.2015.109","article-title":"PPAR\u03b3 ligands increase antileukemic activity of second- and third-generation tyrosine kinase inhibitors in chronic myeloid leukemia cells","volume":"6","author":"Glodkowska-Mrowka","year":"2016","journal-title":"Blood Cancer J"},{"issue":"7569","key":"2019111903584717000_B104","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nature15213","article-title":"Cancer: Repositioned to kill stem cells","volume":"525","author":"Holyoake","year":"2015","journal-title":"Nature"},{"key":"2019111903584717000_B105","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.leukres.2016.03.012","article-title":"BCR\/ABL increases EZH2 levels which regulates XIAP expression via miRNA-219 in chronic myeloid leukemia cells","volume":"45","author":"Nishioka","year":"2016","journal-title":"Leuk Res"},{"issue":"9","key":"2019111903584717000_B106","doi-asserted-by":"crossref","first-page":"3847","DOI":"10.1172\/JCI66129","article-title":"Arachidonate 15-lipoxygenase is required for chronic myeloid leukemia stem cell survival","volume":"124","author":"Chen","year":"2014","journal-title":"J Clin Invest"},{"issue":"7581","key":"2019111903584717000_B107","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/nature15742","article-title":"Barcoding reveals complex clonal dynamics of de novo transformed human mammary cells","volume":"528","author":"Nguyen","year":"2015","journal-title":"Nature"},{"issue":"17","key":"2019111903584717000_B108","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1182\/blood-2014-11-570218","article-title":"Xenograft models for normal and malignant stem cells","volume":"125","author":"Goyama","year":"2015","journal-title":"Blood"},{"issue":"6","key":"2019111903584717000_B109","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.stem.2015.04.004","article-title":"Combined single-cell functional and gene expression analysis resolves heterogeneity within stem cell populations","volume":"16","author":"Wilson","year":"2015","journal-title":"Cell Stem Cell"},{"issue":"37","key":"2019111903584717000_B110","doi-asserted-by":"crossref","first-page":"16280","DOI":"10.1073\/pnas.1004408107","article-title":"Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein","volume":"107","author":"J\u00e4r\u00e5s","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"2019111903584717000_B111","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1158\/1078-0432.CCR-15-0767","article-title":"Identification of CD25 as STAT5-dependent growth regulator of leukemic stem cells in Ph+ CML","volume":"22","author":"Sadovnik","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2019111903584717000_B112","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood.V126.23.49.49","article-title":"CD93 is a novel biomarker of leukemia stem cells in chronic myeloid leukemia","volume":"126","author":"Kinstrie","year":"2015","journal-title":"Blood"},{"issue":"5","key":"2019111903584717000_B113","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1172\/JCI35660","article-title":"Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells","volume":"119","author":"Bellodi","year":"2009","journal-title":"J Clin Invest"},{"issue":"17","key":"2019111903584717000_B114","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1182\/blood-2012-01-402578","article-title":"Autophagic degradation of the BCR-ABL oncoprotein and generation of antileukemic responses by arsenic trioxide","volume":"120","author":"Goussetis","year":"2012","journal-title":"Blood"},{"issue":"6","key":"2019111903584717000_B115","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1080\/15548627.2016.1162359","article-title":"ATG7 regulates energy metabolism, differentiation and survival of Philadelphia-chromosome-positive cells","volume":"12","author":"Karvela","year":"2016","journal-title":"Autophagy"},{"issue":"8","key":"2019111903584717000_B116","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1038\/ng.2350","article-title":"The Blk pathway functions as a tumor suppressor in chronic myeloid leukemia stem cells","volume":"44","author":"Zhang","year":"2012","journal-title":"Nat Genet"},{"issue":"5","key":"2019111903584717000_B117","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1182\/blood-2007-09-112573","article-title":"BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors","volume":"111","author":"Copland","year":"2008","journal-title":"Blood"},{"issue":"10","key":"2019111903584717000_B118","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1182\/blood-2011-06-361261","article-title":"Targeting of GSK3\u03b2 promotes imatinib-mediated apoptosis in quiescent CD34+ chronic myeloid leukemia progenitors, preserving normal stem cells","volume":"119","author":"Reddiconto","year":"2012","journal-title":"Blood"},{"issue":"5","key":"2019111903584717000_B119","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ccr.2010.03.011","article-title":"Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate","volume":"17","author":"Zhang","year":"2010","journal-title":"Cancer Cell"},{"issue":"7198","key":"2019111903584717000_B120","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1038\/nature07016","article-title":"PML targeting eradicates quiescent leukaemia-initiating cells","volume":"453","author":"Ito","year":"2008","journal-title":"Nature"},{"issue":"2","key":"2019111903584717000_B121","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ccr.2011.12.020","article-title":"Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib","volume":"21","author":"Li","year":"2012","journal-title":"Cancer Cell"},{"issue":"2","key":"2019111903584717000_B122","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/cas.12849","article-title":"Novel oral transforming growth factor-\u03b2 signaling inhibitor EW-7197 eradicates CML-initiating cells","volume":"107","author":"Naka","year":"2016","journal-title":"Cancer Sci"},{"issue":"1","key":"2019111903584717000_B123","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1158\/1535-7163.MCT-07-0042","article-title":"CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells","volume":"7","author":"Jin","year":"2008","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"2019111903584717000_B124","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/leu.2011.360","article-title":"Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib","volume":"26","author":"Weisberg","year":"2012","journal-title":"Leukemia"},{"issue":"10","key":"2019111903584717000_B125","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1080\/10428190903150847","article-title":"Plerixafor inhibits chemotaxis toward SDF-1 and CXCR4-mediated stroma contact in a dose-dependent manner resulting in increased susceptibility of BCR-ABL+ cell to Imatinib and Nilotinib","volume":"50","author":"Dillmann","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"2019111903584717000_B126","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.3324\/haematol.2009.017178","article-title":"Bone marrow mesenchymal stromal cells non-selectively protect chronic myeloid leukemia cells from imatinib-induced apoptosis via the CXCR4\/CXCL12 axis","volume":"95","author":"Vianello","year":"2010","journal-title":"Haematologica"},{"issue":"23","key":"2019111903584717000_B127","doi-asserted-by":"crossref","first-page":"3767","DOI":"10.1182\/blood-2013-05-501460","article-title":"Primitive CML cell expansion relies on abnormal levels of BMPs provided by the niche and on BMPRIb overexpression","volume":"122","author":"Laperrousaz","year":"2013","journal-title":"Blood"},{"issue":"11","key":"2019111903584717000_B128","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1182\/blood-2011-10-387381","article-title":"HIF1\u03b1 is required for survival maintenance of chronic myeloid leukemia stem cells","volume":"119","author":"Zhang","year":"2012","journal-title":"Blood"},{"issue":"21","key":"2019111903584717000_B129","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1182\/blood-2013-07-511907","article-title":"Physiologic hypoxia promotes maintenance of CML stem cells despite effective BCR-ABL1 inhibition","volume":"123","author":"Ng","year":"2014","journal-title":"Blood"},{"issue":"26","key":"2019111903584717000_B130","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1056\/NEJMoa1004095","article-title":"Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia","volume":"363","author":"Preudhomme","year":"2010","journal-title":"N Engl J Med"},{"issue":"8","key":"2019111903584717000_B131","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1200\/JCO.2009.25.5075","article-title":"Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia","volume":"28","author":"Burchert","year":"2010","journal-title":"J Clin Oncol"},{"issue":"12","key":"2019111903584717000_B132","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1182\/blood-2011-02-336685","article-title":"Combination of pegylated IFN-\u03b12b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia","volume":"118","author":"Simonsson","year":"2011","journal-title":"Blood"},{"issue":"1","key":"2019111903584717000_B133","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1016\/S2352-3026(14)00027-1","article-title":"Nilotinib and peginterferon alfa-2a for newly diagnosed chronic-phase chronic myeloid leukaemia (NiloPeg): a multicentre, non-randomised, open-label phase 2 study","volume":"2","author":"Nicolini","year":"2015","journal-title":"Lancet Haematol"},{"issue":"9","key":"2019111903584717000_B134","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1038\/leu.2016.121","article-title":"Safety and efficacy of the combination of pegylated interferon-\u03b12b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients","volume":"30","author":"Hjorth-Hansen","year":"2016","journal-title":"Leukemia"},{"issue":"23","key":"2019111903584717000_B135","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1182\/blood-2015-11-679985","article-title":"IL1RAP antibodies block IL-1-induced expansion of candidate CML stem cells and mediate cell killing in xenograft models","volume":"128","author":"\u00c5gerstam","year":"2016","journal-title":"Blood"},{"issue":"23","key":"2019111903584717000_B136","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1182\/blood-2015-11-679928","article-title":"Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor-treated CML stem cells","volume":"128","author":"Zhang","year":"2016","journal-title":"Blood"},{"key":"2019111903584717000_B137","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/1476-4598-13-169","article-title":"Exosomal shuttling of miR-126 in endothelial cells modulates adhesive and migratory abilities of chronic myelogenous leukemia cells","volume":"13","author":"Taverna","year":"2014","journal-title":"Mol Cancer"},{"issue":"17","key":"2019111903584717000_B138","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1182\/blood-2014-06-582924","article-title":"Osteoblast ablation reduces normal long-term hematopoietic stem cell self-renewal but accelerates leukemia development","volume":"125","author":"Bowers","year":"2015","journal-title":"Blood"},{"issue":"3","key":"2019111903584717000_B139","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1172\/JCI79196","article-title":"Heterogeneity of leukemia-initiating capacity of chronic myelogenous leukemia stem cells","volume":"126","author":"Zhang","year":"2016","journal-title":"J Clin Invest"},{"issue":"6","key":"2019111903584717000_B140","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.ccr.2011.05.007","article-title":"Loss or inhibition of stromal-derived PlGF prolongs survival of mice with imatinib-resistant Bcr-Abl1(+) leukemia","volume":"19","author":"Schmidt","year":"2011","journal-title":"Cancer Cell"},{"key":"2019111903584717000_B141","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.516.516","article-title":"The vascular niche is involved in regulating leukemic stem cells in murine chronic myelogenous leukemia","author":"Aggoune","year":"2014"},{"issue":"11","key":"2019111903584717000_B142","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1038\/nm.3364","article-title":"Differential regulation of myeloid leukemias by the bone marrow microenvironment","volume":"19","author":"Krause","year":"2013","journal-title":"Nat Med"},{"issue":"4","key":"2019111903584717000_B143","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1182\/blood-2013-06-506097","article-title":"TWIST it but don\u2019t spin it","volume":"122","author":"Apperley","year":"2013","journal-title":"Blood"},{"issue":"20","key":"2019111903584717000_B144","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","article-title":"Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis","volume":"26","author":"de Lavallade","year":"2008","journal-title":"J Clin Oncol"},{"issue":"10","key":"2019111903584717000_B145","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1038\/leu.2008.225","article-title":"A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials","volume":"22","author":"Lucas","year":"2008","journal-title":"Leukemia"},{"issue":"1","key":"2019111903584717000_B146","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/j.1365-2141.2011.08653.x","article-title":"Restricted access to second generation tyrosine kinase inhibitors in the UK could result in suboptimal treatment for almost half of chronic myeloid leukaemia patients: results from a West of Scotland and Lothian population study","volume":"155","author":"Gallipoli","year":"2011","journal-title":"Br J Haematol"},{"issue":"12","key":"2019111903584717000_B147","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.1634\/stemcells.2007-0250","article-title":"Transcriptional analysis of quiescent and proliferating CD34+ human hemopoietic cells from normal and chronic myeloid leukemia sources","volume":"25","author":"Graham","year":"2007","journal-title":"Stem Cells"},{"issue":"3","key":"2019111903584717000_B148","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.stem.2013.06.009","article-title":"Myeloproliferative neoplasia remodels the endosteal bone marrow niche into a self-reinforcing leukemic niche","volume":"13","author":"Schepers","year":"2013","journal-title":"Cell Stem Cell"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/129\/12\/1595\/1399533\/blood696013.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/129\/12\/1595\/1399533\/blood696013.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T03:59:28Z","timestamp":1574135968000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/129\/12\/1595\/36129\/The-chronic-myeloid-leukemia-stem-cell-stemming"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,23]]},"references-count":148,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,3,23]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2016-09-696013","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,23]]}}}